Find Neomycin Sulfate Tablet, Intestinal Infection, Colonic Operation on Industry Directory, Reliable Manufacturer/Supplier/Factory from China.

Inquiry Basket (0)
Home > Products > Gastro-Intestinals Drug > 300mgi/Ml Omnipaque Iohexol Injection for X Ray Contrast Medium

300mgi/Ml Omnipaque Iohexol Injection for X Ray Contrast Medium

Basic Info

Model No.:  DAWAOII0001

Product Description



Model NO.: DAWAOII0001


Usage Mode: For external use


State: Liquid


Type: Biological Products


Administration Route: I.V


OEM: Acceptable


Transport Package: 1 Bottle / Box


Origin: France




Application: Surgery


Suitable for: Elderly, Children, Adult


Shape: I.V


Pharmaceutical Technology: Chemical Synthesis


MOQ: 10 Box


Trademark: Nipaque


Specification: 300mgI/ml, 100ml


HS Code: 3002100000


300mgI/ml Omnipaque Iohexol Injection For X Ray Contrast Medium

Specification: 300mgI/ml , 100ml
Package 1 Bottle / Box




Iohexol is a contrast agent, sold under the trade names Omnipaque and Exypaque; this compound is also sold as a density gradient medium under the names Accudenz, Histodenz and Nycodenz. It is available in various concentrations, from 140 to 350 milligrams of iodine per milliliter. Omnipaque 350 is commonly used as a contrast agent during coronary angiography.



Drug Interactions

Drugs which lower seizure threshold, especially phenothiazine derivatives including those used for their antihistaminic or antinauseant properties, are not recommended for use with OMNIPAQUE. Others include monoamine oxidase (MAO) inhibitors, tricyclic antidepressants, CNS stimulants, psychoactive drugs described as analeptics, major tranquilizers, or antipsychotic drugs. Such medications should be discontinued at least 48 hours before myelography, should not be used for the control of nausea or vomiting during or after myelography, and should not be resumed for at least 24 hours postprocedure. In nonelective procedures in patients on these drugs, consider prophylactic use of anticonvulsants



DOSAGE AND ADMINISTRATION

As with all radiopaque contrast agents, the lowest dose of OMNIPAQUE necessary to obtain adequate visualization should be used. A lower dose may reduce the possibility of an adverse reaction. Most procedures do not require use of either the maximum volume or the highest concentration of OMNIPAQUE. The combination of volume and concentration of OMNIPAQUE to be used should be carefully individualized accounting for factors such as age, body weight, size of the vessel and the rate of blood flow within the vessel. Other factors such as anticipated pathology, degree and extent of opacification required, structure(s) or area to be examined, disease processes affecting the patient, and equipment and technique to be employed should be considered.

Sterile technique must be used in all vascular injections involving contrast media.

Refer to DIRECTIONS FOR PROPER USE OF OMNIPAQUE PHARMACY BULK PACKAGE section for instructions.

If nondisposable equipment is used, scrupulous care should be taken to prevent residual contamination with traces of cleansing agents.

It may be desirable that solutions of radiopaque diagnostic agents be used at body temperature when injected.

Parenteral products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Solutions of OMNIPAQUE should be used only if clear and within the normal colorless to pale yellow range. If particulate matter or discoloration is present, do not use.

Contact us if you need more details on Omnipaque. We are ready to answer your questions on packaging, logistics, certification or any other aspects about Iohexol、Contrast Agent. If these products fail to match your need, please contact us and we would like to provide relevant information.

Product Categories : Gastro-Intestinals Drug